IL138615A0 - Alphaviral gene expression system and dna molecules for use therein - Google Patents

Alphaviral gene expression system and dna molecules for use therein

Info

Publication number
IL138615A0
IL138615A0 IL13861599A IL13861599A IL138615A0 IL 138615 A0 IL138615 A0 IL 138615A0 IL 13861599 A IL13861599 A IL 13861599A IL 13861599 A IL13861599 A IL 13861599A IL 138615 A0 IL138615 A0 IL 138615A0
Authority
IL
Israel
Prior art keywords
rna molecules
gene expression
untranslated
methods
expression system
Prior art date
Application number
IL13861599A
Other languages
English (en)
Original Assignee
Cytos Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag filed Critical Cytos Biotechnology Ag
Publication of IL138615A0 publication Critical patent/IL138615A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL13861599A 1998-03-27 1999-03-25 Alphaviral gene expression system and dna molecules for use therein IL138615A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7956298P 1998-03-27 1998-03-27
PCT/IB1999/000523 WO1999050432A1 (en) 1998-03-27 1999-03-25 Inducible alphaviral gene expression system

Publications (1)

Publication Number Publication Date
IL138615A0 true IL138615A0 (en) 2001-10-31

Family

ID=22151327

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13861599A IL138615A0 (en) 1998-03-27 1999-03-25 Alphaviral gene expression system and dna molecules for use therein

Country Status (10)

Country Link
US (2) US7005275B2 (de)
EP (1) EP1066395B1 (de)
JP (2) JP2002509729A (de)
AT (1) ATE304603T1 (de)
AU (1) AU757549B2 (de)
CA (1) CA2325564A1 (de)
DE (2) DE69927249T2 (de)
IL (1) IL138615A0 (de)
NZ (1) NZ507195A (de)
WO (1) WO1999050432A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927249T2 (de) * 1998-03-27 2006-06-29 Cytos Biotechnology Ag Induzierendes alphavirengen- expressionssystem
US7241617B2 (en) * 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
KR20010074631A (ko) * 1998-07-03 2001-08-04 가부시끼가이샤 디나벡 겡뀨쇼 신경세포용 （－）쇄 ｒｎａ 바이러스 벡터
JP2002521461A (ja) 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
AU7938900A (en) * 1999-10-27 2001-05-08 Cytos Biotechnology Ag Method for creating divergent populations of nucleic acid molecules and proteins
WO2001042442A2 (en) * 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003023026A1 (en) * 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
EP1530585A2 (de) * 2002-08-22 2005-05-18 Cytos Biotechnology AG Induzierbares alphaviral/orip basiertes gen expressionssystem
WO2005005644A1 (en) 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
WO2016209989A1 (en) * 2015-06-26 2016-12-29 The Regents Of The University Of California Methods for rna promoter identification
US9859156B2 (en) * 2015-12-30 2018-01-02 Taiwan Semiconductor Manufacturing Co., Ltd. Interconnection structure with sidewall dielectric protection layer
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
WO2023034881A1 (en) * 2021-09-02 2023-03-09 Elixirgen Therapeutics, Inc. Temperature-controllable, rna immunotherapeutic for cancer
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ES2328424T3 (es) 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. Vectores de alfavirus recombinantes.
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
DE69927249T2 (de) * 1998-03-27 2006-06-29 Cytos Biotechnology Ag Induzierendes alphavirengen- expressionssystem

Also Published As

Publication number Publication date
US20030053988A1 (en) 2003-03-20
DE1066395T1 (de) 2002-04-04
US7005275B2 (en) 2006-02-28
WO1999050432A1 (en) 1999-10-07
AU757549B2 (en) 2003-02-27
ATE304603T1 (de) 2005-09-15
DE69927249D1 (de) 2005-10-20
JP2002509729A (ja) 2002-04-02
EP1066395B1 (de) 2005-09-14
CA2325564A1 (en) 1999-10-07
JP2005323620A (ja) 2005-11-24
DE69927249T2 (de) 2006-06-29
EP1066395A1 (de) 2001-01-10
AU2848199A (en) 1999-10-18
NZ507195A (en) 2003-07-25
US20060024788A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
IL138615A0 (en) Alphaviral gene expression system and dna molecules for use therein
Piñeiro et al. Fifteen years of prothymosin alpha: contradictory past and new horizons
Paterson et al. Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
JP6284181B2 (ja) 環状ｒｎａ及びタンパク質の製造方法
Wengler et al. Identification of a transfer of viral core protein to cellular ribosomes during the early stages of alphavirus infection
FI932678A7 (fi) Alfaviruksiin perustuvia DNA-ilmentämissysteemejä
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
SI1675956T1 (sl) Minimalno zaporedje dna, ki deluje kot izolirni element kromatina in njegova uporaba pri ekspresiji proteinov
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
Smolar et al. DNA sequences of polyoma virus early deletion mutants
ES2054612T3 (es) Secuencias de adn que codifican para proteinas con actividad biologica de los inhibidores husi tipo-i y procedimientos tecnologicos geneticos para la preparacion de estas proteinas.
SE0102204D0 (sv) New method
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
WO2005002511A3 (en) Recombinant antibodies and compositions and methods for making and using the same
DE60029325D1 (en) Typ ii dns polymerase aus pyrococcus abyssi
EP0770137A4 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
Honjo et al. Purification and translation of an immunoglobulin λ chain messenger RNA from mouse myeloma
BR0107655A (pt) Polinucleotìdeo isolado, vetor de expressão recombinante, polipeptìdeo, célula, método para produzir o polipeptìdeo, e, composição farmacêutica
Erhan Model for DNA Polymerase
Simon et al. Induction of T cell serine proteinase 1 (TSP‐1)‐specific mRNA in mouse T lymphocytes
ATE315406T1 (de) Semi-allogene antitumor-vakzine mit hla-haplo- identischen antigen-präsentierenden zellen
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
Davern et al. Nucleic acids and proteins